



Syndicated Thought Leader Insight

---

**Thought Leader Insight & Analysis Report  
Rheumatology Q4 2009**

**Therapeutic Class:** Autoimmune Disorders  
**Focus Area:** Rheumatoid Arthritis, Lupus, Vasculitis, Polymyositis, Scleroderma  
**Specialty/Location:** Rheumatologists / North America, Europe  
**Number of Interviews:** 6  
**Number of Pages:** 129  
**Publication Date:** December 2009  
**Principal Authors:** Kim Grant  
Tricia L. Hanlon  
Jeffrey D. Berk, Ph.D., MBA  
**Product Code:** MAIRQ409-28  
**Pricing:** \$7,000  
**Order Info:** www.medpredict.com or call (513) 271-1924

**Abstract:** This report is based on 6 interviews conducted with American and European rheumatology thought leaders following the American College of Rheumatology (ACR) 2009 meeting. The Panel highlights key learnings from the meeting, focusing on data that suggests any advantage for newer biologicals and small molecules compared to the standards of care for the treatment of rheumatoid arthritis. The Thought Leaders also provide insight into divergent activities and results pertaining to lupus, vasculitis, polymyositis and scleroderma.

Mechanisms discussed by this Panel include:

- BLYS
- CCR
- CD20
- CTLA4
- GMCSF
- JAK
- IL-6 / IL-17
- Interferon
- MEK
- PDE4
- RANKL
- Syk
- TNF

***This report provides essential strategic insight for key stakeholders in the rheumatology market at a significant value versus customized primary research.***

**Drugs/Mechanisms Discussed in this Report:**

<b>Company</b>	<b>Drug</b>	<b>Brand</b>
Abbott	adalimumab	Humira
Alder / BMS	ALD-518	
Amgen / Wyeth / Pfizer	etanercept	Enbrel
Array	ARRY-438162	
Bristol-Myers Squibb	abatacept	Orencia
Celgene	apremilast	
Centocor / Schering-Plough (Merck)	infliximab golimumab	Remicade Simponi
Genentech / Roche	rituximab ocrelizumab PRO-131921 rontalizumab (rhuMAb IFN alpha) BAFF inhibitor	Rituxan / MabThera
Genentech / Roche / Chugai	tocilizumab	Actemra / RoActemra
GlaxoSmithKline / Human Genome Sciences	belimumab	Benlysta
Incyte / Novartis (for cancer only)	INCB-18424	
Incyte / Lilly (for non-cancer only)	INCB-28050	
La Jolla / Adamis	abetimus; LJP-394	Riquent
Lilly	LY2439821 LY2127399; BAFF antibody	
Medimmune	sifalimumab (MEDI-545)	
Merck Serono	atacept	
Millennium / Takeda	MLN-3897	
Morphosys	MOR-103	
Novartis	AIN-457	
Pfizer	CP-690550 WYE-152038 maraviroc etanercept	Selzentry Enbrel
Rigel	fostamatinib (R788)	
Trubion / Pfizer	TRU-015	
UCB	certolizumab	Cimzia

## Table of Contents

Executive Summary.....	4
Top Ten Report Highlights .....	6
Key Findings.....	16
Lupus / Vasculitis / Polymyositis / Scleroderma.....	16
Benlysta; belimumab (Human Genome Sciences / GlaxoSmithKline) .....	16
Rituxan (rituximab; Genentech / Biogen-Idec).....	21
atacept (Merck Serono).....	23
ocrelizumab (Genentech / Biogen-Idec) .....	25
PRO131921 (Genentech) .....	25
LY2127399; BAFF Antibody (Lilly) .....	26
BAFF Inhibitor (Genentech).....	28
Riquent (abetimus; LJP-394; La Jolla Pharmaceuticals / Adamis).....	28
CTLA4.....	29
Orencia (abatacept; BMS) .....	29
IL-6.....	29
Actemra (tocilizumab; Chugai / Roche) .....	29
Interferon (inhibition) .....	30
sifalimumab (MEDI-545; Medimmune) .....	30
Rontalizumab (rhuMAb IFN alpha); Genentech .....	31
Rheumatoid Arthritis / Psoriatic Arthritis .....	32
Management of Cardiovascular Risk Factors.....	32
Oral Therapies .....	33
B-cell .....	34
MabThera / Rituxan (rituximab; Genentech / Biogen-Idec) .....	34
ocrelizumab (Genentech) .....	36
TRU-015 (Pfizer / Trubion) .....	38
CCR .....	38
MLN-3897 .....	38
Selzentry (maraviroc; Pfizer) .....	40
CTLA4.....	40
Orencia; abatacept (BMS) .....	40
GMCSF .....	41
MOR-103 (Morphosys) .....	41
IL-6.....	42
Actemra (tocilizumab; Roche / Chugai) .....	42
ALD-518 (Alder / BMS) .....	44
IL-17 .....	45
LY2439821 (Lilly) / AIN-457 (Novartis).....	45
Interferon.....	46
sifalimumab (MEDI-545; Medimmune) .....	46
JAK.....	47
CP-690550 (Pfizer) .....	47
INCB-18424 (Incyte) .....	53
INCB28050 (Lilly / Incyte) .....	54
WYE-152038 (Wyeth / Pfizer).....	55
MEK .....	55
ARRY-438162 (Array).....	55
RANKL .....	57
Prolia; denosumab (Amgen / Daiichi Sankyo / Dompe) .....	57
Syk .....	58
fostamatinib (Rigel).....	58

TNF / PDE4 .....	60
Enbrel (etanercept; Amgen / Pfizer) / Humira (adalimumab; Abbott) .....	60
apremilast (Celgene) .....	68
Cimzia (certolizumab; UCB) .....	69
Thought Leader Interviews .....	72
Interview BJE02361 .....	72
Interview BJE02362 .....	82
Interview BJE02366 .....	92
Interview BJE02372 .....	102
Interview BJE02373 .....	112
Interview BJE02374 .....	122